India Exempts Rare Disease Drugs, Keytruda From Customs Duty - Is It Enough?

India, China Likely Have Largest Numbers Of Rare Disease Patients

India has exempted imports of top-selling oncology drug Merck’s Keytruda from customs duty as also rare disease drugs listed in the National Policy For Rare Diseases. However, patient advocacy groups feel more fiscal measures and manufacturing incentives are needed to improve access  

Red Chess Piece Among White Ones
Tackling Rare Diseases Needs More Policy Measures, Fiscal Incentives • Source: Shutterstock

A recent move by the Indian government to exempt customs duty on drugs and food items prescribed for special medical purposes and imported for personal use to treat rare diseases listed in the National Policy For Rare Diseases, 2021 is a win for groups that have been working to sensitize policy makers and regulators to the needs of rare disease patients.

Along with these drugs, Keytruda (pembrolizumab) from MSD, as Merck & Co., Inc. is known outside US and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet